Elevai Labs, Inc. (NASDAQ:ELAB) Short Interest Down 89.6% in February

Elevai Labs, Inc. (NASDAQ:ELAB) saw a significant drop in short interest in February. As of February 28th, there was short interest totalling 19,400 shares, a drop of 89.6% from the February 13th total of 185,700 shares. Based on an average daily trading volume, of 302,600 shares, the short-interest ratio is presently 0.1 days. Approximately 0.6% of the shares of the stock are sold short.

Elevai Labs Trading Down 12.7 %

NASDAQ:ELAB traded down $0.60 on Wednesday, reaching $4.11. The stock had a trading volume of 75,972 shares, compared to its average volume of 311,430. Elevai Labs has a 12-month low of $3.88 and a 12-month high of $1,134.00. The company has a market cap of $2.38 million, a price-to-earnings ratio of -0.07 and a beta of -2.93. The firm’s fifty day moving average is $12.36 and its two-hundred day moving average is $97.62. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.86 and a quick ratio of 3.40.

About Elevai Labs

Elevai Labs, Inc, a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc and changed its name to Elevai Labs, Inc in December 2021.